





















A **miR-1287-5p expression****B** **P<0.0001****C****D****E**

A**Relative miR-1287-5p expression in BC cell lines**











A**SUM159****C****MDA-MB-468****B****BT549****D****MDA-MB-231**






Xenografts of miR-1287 precursor overexpression SUM159




A**Caspase 3/7 assay: transient transfections****B****Caspase 3/7 assay: lentiviral miR-1287 precursor overexpressing cell lines****C****Caspase 3/7 assay: lentiviral miR-1287-5p overexpressing cell lines**

Stable transfection:

A SUM159




B MDA-MB-231




Transient transfection:

C SUM159




D BT549




SUM159


A ■ Control ■ miR-1287-5p inhibitor ■ miR-1287-5p mimic

**MDA-MB-231**




B ■ Control ■ miR-1287-5p inhibitor ■ miR-1287-5p mimic

**SUM159**


C ■ Control ■ miR-1287-5p overexpression

**MDA-MB-231**

D ■ Control ■ miR-1287-5p overexpression


**E****F**

212688_at














	Number at risk					
	0	50	100	150	200	250
low	2639	1769	775	171	17	1
high	1312	750	300	70	10	2

212688_at



	Number at risk						
low	817	650	294	83	16	2	0
high	585	433	183	46	5	1	0



A**B****C****D**